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Background
Drugs can affect the growing fetus at any time during
pregnancy. The period of greatest risk for congenital
anomalies is the first trimester (3 months) of pregnancy,
which is the time of organ development. As women may
not realize they are pregnant for some time into the first
trimester, prescribers must be cautious when prescrib-
ing for all women of childbearing age and men trying to
father a child (British National Formulary 2010).
Thalidomide was prescribed in the late 1950s for
pregnant women suffering with morning sickness and
was also available as an over-the-counter drug in some
countries. Unfortunately, during the following years
Correspondence
Margery Morgan
CARIS – the Congenital Anomaly







For the EUROmediCAT Steering Group.
Members of the EUROmediCAT
Steering Group: Helen Dolk, Maria
Loane and Marlene Sinclair, University
of Ulster, UK;Marian Bakker, University
Medical Center, Groningen, The
Netherlands; Corinne de Vries,
University of Bath, UK; Ester Garne,
Lillebaelt Hospital Kolding, Denmark;
Anna Latos Bielenski, University,
Poznan, Poland; Sue Jordan, Swansea
University, UK; Anna Pierini, Consiglio
Nazionale della Richerche, Italy; Joan
Morris, Wolfson Institute of Preventive
Medicine, London, UK; Awi Wiesel,
University of Mainz, Germany.
MORGAN M. , DE JONG-VAN DEN BERG L .T .W . & JORDAN S . (2011) Journal of Nursing
Management 19, 305–310
Drug safety in pregnancy – monitoring congenital anomalies
Aim This paper outlines research into the causes of congenital anomalies, and
introduces a pan-European study. The potential roles of nurses and midwives in this
area are illustrated by a case report.
Background Since the thalidomide disaster, use of drugs in pregnancy has been
carefully monitored to prevent anything similar happening again. However, moni-
toring is incomplete and questions remain unanswered.
Key issues Many medicines are essential for the health of pregnant women. How-
ever, drug use in pregnancy requires surveillance. Methods include spontaneous
reporting of adverse events, cohort studies and case control studies. It is hoped that
a Europe-wide study, combining data from several congenital anomaly registers,
will provide a sufficiently large population to assess the impact of selected drugs on
congenital anomalies. However, this work depends on the consistency of reporting
by nurses and midwives.
Conclusion Drug safety in pregnancy remains undetermined. Collaboration across
Europe has the potential to provide a framework for safety evaluation.
Implications for nursing management Prescribers should consider the possibility of
pregnancy in women of child-bearing age. Careful review of maternal drug use in
early pregnancy is essential. Midwives and nurses should be aware of adverse event
drug reporting systems, including congenital anomaly registers.
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many children were born with congenital anomalies,
particularly phocomelia, a limb reduction defect. The
National Congenital Anomalies System was set up in
England and Wales in 1964 to provide surveillance of
all congenital anomalies born and be in a position to
prevent a similar disaster. Drug companies from then on
had to comply with stricter reproductive toxicity
testing.
Currently, drugs are tested in the reproductive period
by animal studies only. As a result, the chances of
predicting a problem with the developing human fetus
is limited. Pregnant women, understandably, are ex-
cluded from drug trials.
Knowing the pharmacology and toxicology of tha-
lidomide did not predict the resulting anomalies so,
unfortunately, these adverse effects may only be dis-
covered after a drug has been used in human pregnancy
(Mitchell 2003).
The question in early pregnancy that prescribers
(including non-medical prescribers) ask is: Is this drug
really necessary? If there is any doubt then most clini-
cians would not prescribe. However, for women with
chronic diseases such as diabetes, epilepsy and asthma,
continuing medication is necessary for maintaining
maternal health and hence fetal wellbeing. Other
women may be on long-term treatment for depression
or anxiety or require regular analgesia. Pre-conception
counselling is important to avoid exposing the devel-
oping fetus to drugs without a safety track record in
pregnancy. It is also an opportunity to prescribe folic
acid, particularly the increased dose for diabetics and
epileptics to reduce the risk of neural tube defects in the
fetus (British National Formulary 2010).
Drugs in pregnancy
The most widely used publication for advice on drugs in
pregnancy in the United Kingdom is the British Na-
tional Formulary (BNF). Recently, the format has
changed. The pregnancy advice has been taken from the
appendices and is now with each individual drug. The
research evidence for the effects of drugs on mother and
baby is reviewed elsewhere (Jordan 2010).
Pregnancy, childbirth, breastfeeding and developing
infants may be affected by medicines or environmental
exposure. The impact of medication on the fetus may
include congenital anomalies, prematurity, low birth
weight and developmental delay. As the ova of female
infants are formed before birth, there is potential for
prenatal exposures to affect subsequent generations.
Manufacturers of many drugs and herbal remedies
advise against use in pregnancy and lactation on the
grounds that there are insufficient human data to
demonstrate safety. No drugs have been subjected to
randomized controlled clinical trials for teratogenicity
in human pregnancy. Therefore, no drug has been
demonstrated as safe. The evidence for transgenera-
tional adverse drug reactions is largely derived from
case reports of incidental exposure, observation studies,
usually based on databases from Scandinavian coun-
tries, and animal studies.
Relatively few drugs are known to cause congenital
anomalies, but only drugs that have been used for many
years in thousands of women with no evidence of harm
can be designated generally regarded as safe. In reality,
no drugs always harm the developing fetus all the time.
Estimates vary as to the incidence of congenital mal-
formations: up to 30% with warfarin, up to 16% with
sodium valproate (Aronson 2006). Drugs associated
with anomalies include:
• Warfarin (used to prevent venous thrombosis) – can
cause the fatal warfarin syndrome, which includes
nasal hypoplasia, eye defects, heart problems, limb
shortening, deafness, scoliosis and seizures.
• Isotretinoin (treatment for severe acne) – can cause
defects that include hydrocephalus, blindness, facial
problems, cleft palate, deafness, heart defects and
spina bifida.
• Valproic acid (anti epileptic drug) – can cause neural
tube defects, cardiac defects, facial problems, renal
problems, limb, skull and muscle defects.
• Drugs acting on the renin–angiotensin system,
prescribed for hypertension or heart failure (Appen-
dix 1 ).
The importance of this work is illustrated by the case
described in Appendix 1. This case emphasizes the
importance of good communication facilitating an
accurate drug history. In the UK this is usually taken by
the midwife early in pregnancy.
Drug safety studies
At present there are three approaches to identifying the
risks of drugs in pregnancy. These are outlined below.
Spontaneous adverse event reporting
Events are reported voluntarily but their validity is
compromised by an unknown denominator number (the
total number of women taking the drug in early preg-
nancy). This reporting of cases can act as a very useful
early warning sign, particularly where there is a high
risk of a specific anomaly. Anomalies can be reported
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by all health-care professionals. Where available, the
local congenital anomaly register should be alerted to
any such anomalies, suspected or confirmed. However,
spontaneous reporting relies on the cooperation of busy
clinicians. In addition, when reports are made, up to a
year after birth, the mother may have forgotten what
medicines she was receiving during early pregnancy.
Therefore, a thorough drug history in early pregnancy is
very important: this will be available for review if a
congenital anomaly occurs.
Cohort studies
These studies follow women taking a certain drug and
record the pregnancy outcome compared with a group
not taking the drug. Follow up of both groups is
essential. A disadvantage here is that for a drug to de-
tect a moderate or low risk of causing an anomaly a
large cohort is necessary. Obstetricians specializing in
medical disorders of pregnancy may maintain detailed
records of all affected pregnant women in their area.
The processes and outcomes of care can then be anal-
ysed and compared with outcomes for the population as
a whole. However, even over 10–20 years, there will be
too few cases of congenital anomalies in medium-sized
hospitals for any useful statistical testing. Also, from
our experience, not all women take this opportunity to
receive specialist care: the women most at risk – those
least motivated to take care during pregnancy – do not
regularly attend consultants clinics. This is particularly
important for conditions such as diabetes, where poor
glycaemic control in the mother can have serious ad-
verse effects on the pregnancy and fetus.
Case–control studies
These review cases of pregnancies where a baby is born
with a specific congenital anomaly and compare them
with controls in terms of medication usage. Controls
can be normally formed births or births with other
anomalies. Case–control studies have more statistical
power to detect moderate to low risk of anomalies than
cohort studies. An example of such a study is described
as follows.
EUROmediCAT – a European approach to drug
safety in pregnancy
The European Surveillance of Congenital Anomalies
(EUROCAT, http://www.eurocat-network.eu) is a net-
work of population-based congenital anomaly registers
covering nearly one-third of all births in 20 European
countries (Figure 1). This amounts to 1.5 million births
per year. Started in 1979, EUROCAT was developed to
provide epidemiological surveillance of all congenital
anomalies. In recent years drug information has been
enhanced on the central register enabling, for example,
investigations on antiepileptic drugs and their risks
(Dolk et al. 2008, Jentink et al. 2010a,b). For many
European countries only certain areas are covered by
EUROCAT. Whole population coverage is achieved in
Scandinavian countries, and Wales. This is a very
important consideration for statisticians interpreting
the data.
The EUROmediCAT study aims to build a Euro-
pean system to check the safety of drugs in pregnancy.
It will provide a system for informing risk–benefit
profiles of medicines in relation to congenital anom-
alies to a much fuller extent. The central aim is to
build a European system for reproductive safety
evaluation that enables us to identify systematically
and comprehensively the possible adverse effects in
pregnancy of a drug in humans at the earliest stage
post-marketing, and to monitor and evaluate safety
measures undertaken in Europe. The specific objec-
tives are:
• To develop and test an efficient system for safety
evaluation of drugs during pregnancy, based on the
EUROCAT network of congenital anomaly registers
combined with existing population-based databases
with information on drugs prescribed.
• To assess the risk of congenital anomaly in all drugs
with particular emphasis on certain groups of drugs:
s Anti-epileptic drugs (particularly newer drugs, e.g.
lamotrigine).
s Insulin analogues (because the safety of long-
acting analogues is not established).
s Anti-asthmatic drugs (there is increased usage as
asthma increases in the population.
s Anti-depressant drugs (possible link to cardiac
anomalies in the baby with selective serotonin
reuptake inhibitors).
These drugs have been selected because they are
commonly prescribed to young women and case reports
and small cohort studies have engendered concern over
use in pregnancy. Only a large dataset will be able to
provide an assessment of impact.
• To evaluate the efficacy of pregnancy-related drug
safety measures, including pregnancy-prevention
programmes. These are in place for thalidomide
(used in myeloma), isotretinoin (acne) and acitretin
Drug safety in pregnancy
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(psoriasis). Pregnancy-prevention programmes apply
to drugs known to have a teratogenic effect on the
developing fetus. The instructions accompanying
these drugs state clearly the need to prevent preg-
nancy and the time to wait after ceasing drug
treatment before attempting a pregnancy. Women
are instructed to perform regular pregnancy testing
and are recommended to use the safest contraceptive
techniques.
We propose to interrogate our databases to identify
any instances of pregnancy among women prescribed
these drugs, and the use of prescribed contraceptives
among these women. The study will also evaluate in-
ternet access by pregnant women to drugs and safety
information about drugs.
Data is supplied by the individual congenital anomaly
registers to the EUROCAT central database, which has
strict data quality. The data is obtained from various
sources: birth registers, inpatient data, midwives, pae-
diatric nurses, obstetricians and paediatricians report-
ing to congenital anomaly registers. Uniquely,
EUROmediCAT will analyse this data in association
with information on prescriptions issued in pregnancy
to affected and unaffected women. Researchers will
work only with anonymized data. The study is due to
start in the spring of 2011 and run for 4 years.
Limitations
Work on databases is limited by failure of spontaneous
reporting and incomplete population coverage, for
example in the UK. The UK cannot participate in EU-
ROmediCAT as a whole, as the area is not completely
covered by a congenital anomaly register. The National
Congenital Anomaly System set up after the thalidomide
disaster in England and Wales has recently ceased pro-
viding surveillance. At present Wales is the only register
suitable to participate. TheCongenital AnomalyRegister
and Information Service for Wales (CARIS) is a multiple
source reporting congenital anomaly register with cov-
erage of all babies with congenital anomalies born to
mothers normally resident in Wales (CARIS 2010). The
register includes terminations of pregnancy and sponta-
neous fatal losses. It records maternal details including
drug usage and health issues. In England only 50% of
births occur in areaswith established congenital anomaly
registers. Most of these registers do not record maternal
drug usage. East Anglia, London and the South East do
Figure 1
EUROCAT congenital anomaly registers.
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not have a register. In Scotland, congenital anomaly data
is derived from routine data systems and provided by the
Information Services Division, National Health Service
(NHS) Services, Scotland. Northern Ireland has no con-
genital anomaly register.
The causes of most congenital anomalies remain un-
known, and it may not be possible to obtain informa-
tion on all putative influences. For example, some work
has implicated landfill sites (Palmer et al. 2005), and
information on such exposure is not always available or
would require extensive meteorological or hydrological
data to determine exposure. Whether collected by
spontaneous reports or hospital records, certain infor-
mation may be poorly recorded. For example, maternal
reporting, may seriously underestimate the incidence of
use of amphetamines, opiates and cocaine (Burns et al.
2006), making it difficult to assess the impact of these
possible alternative causes of anomalies (Rasmussen &
Frı´as 2008). Resource limitations also mean that not all
drugs can be considered within any single project.
Conclusion
The evaluation of drug safety in pregnancy remains a
challenge. This new study involving collaboration of
congenital anomaly registers in Europe will facilitate
closer scrutiny of adverse effects of drugs taken in preg-
nancy. Meanwhile, health-care professionals should
reflect on their role in medicines management for
women of child-bearing age.
Implications for nurse and midwife managers
Constant vigilance is essential when discussing medi-
cations with any woman who could be pregnant or
considering pregnancy, as the case study in Appendix 1
illustrates. Policies and procedures are needed to ensure
that:
• Prescribers (including non-medical prescribers)
ascertain the date of last menstrual period and, if
appropriate, discuss the possibility of pregnancy
before any new medicine is prescribed and remind
women of the importance of pre-conception coun-
selling when issuing repeat prescriptions.
• Midwives listing drugs currently administered dur-
ing the initial booking of the pregnancy appoint-
ment ensure that appropriate checks are undertaken
(Appendix 1).
• All health-care practitioners report congenital
anomalies to the appropriate national or regional
registers at the earliest possible opportunity. If data
are incomplete, it will be impossible to establish the
causes of congenital anomalies. Adverse reactions
including congenital anomalies thought to be due
to a drug should be reported using the UK yellow
card system (MHRA 2010).
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Appendix 1
Case study
Mrs R was a 30-year-old Asian woman with very little
English. She was expecting her third child, having had
two healthy babies in 2002 and 2004. Since the last
pregnancy she had developed hypertension, treated by
her general practitioner (GP) with olmesartan (angio-
tensin II receptor antagonist). This was recorded by the
midwife at a booking visit done with an interpreter at
11 weeks gestation. The aspirin she was taking for
migraines was stopped by her GP following this. She
continued taking olmesartan. At 20 weeks the anomaly
scan of the baby showed a reduced amount of amniotic
fluid. A repeat scan, 2 weeks later, showed the
appearance of no fluid at all. The kidneys were thought
to be normal but the bladder difficult to outline. This
suggested a problem with renal function. After further
scans at the tertiary centre the parents decided to ter-
minate the pregnancy because of the poor prognosis in
terms of pulmonary hypoplasia (lung development is
compromised by reduced amniotic fluid). This was at
26 weeks gestation.
While inducing labour following feticide it was no-
ticed Mrs R was taking her own supply of olmesartan.
This was brought to the attention of her team who were
surprised by this. The drug is contraindicated in preg-
nancy and its effects could have caused the renal
problems of the baby. Unfortunately, the parents de-
clined a post-mortem to confirm this.
Olmesartan
Olmesartan is an antihypertensive drug of the angio-
tensin II receptor antagonist group. The British Na-
tional Formulary (2010) advises to avoid prescribing in
pregnancy because of adverse effects on fatal blood
pressure control and renal function. It can also cause
oligohydramnios (reduced amniotic fluid) and possible
skull defects.
Case reports have shown renal failure in babies where
the mother has taken drugs in this group beyond
20 weeks gestation. Stopping the drug in the first tri-
mester gives an improved outcome but the advice re-
mains to avoid angiotensin II receptor antagonists at
any time in pregnancy (Chow & Lam 2004, Cooper
et al. 2006).
Implications for practice
Several senior health professionals missed the impor-
tance of the drug history as she was recorded as not
taking any drugs in one section of the notes and the
drug itself was recorded in a different section concern-
ing medications. Language difficulties may have played
a part in this.
Counselling before conception is recommended for all
diabetic mothers (Diabetes in Pregnancy, NICE Guide-
line 2008) and may have been useful here and for all
mothers taking medications to consider changes in
therapy in pregnancy.
M. Morgan et al.
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